Responsible for Discovery strategy, oversight, and advancement of allogeneic cord blood NK (CBNK) cell therapy platform. Set near-term goals and long-term vision for internal CBNK pipeline programs.• Led Takeda’s first internal end-to-end CBNK pipeline program from project start (PS) to candidate selection (CS), overseeing construct design & optimization, identifying and addressing program gaps, and directing execution of in vitro and in vivo POC studies to support advancement as a Development candidate• Direct internal CBNK program leads in generating concise, stage-appropriate data packages that inform on key MOA and support program Go/No-Go decisions at critical milestones in a timely manner• Research lead on two Global Program Teams for CBNK assets (one in Phase 1 clinical testing and the other advancing to an IND filing), ensuring appropriate non-clinical data is generated to support proposed MOA and near/long-term clinical development plans (e.g., synergistic combination agent prioritization, optimal dosing strategies) • Research lead for Heme Disease Area Strategy group, tasked with defining optimal ‘white spaces’ within heme indications to target based on patient unmet need and asset target product profiles• Responsible for crafting and authoring Pharmacology section of two cell therapy IND filings• Serve as CBNK platform liaison for external collaborations• Support business development and external innovation functions in search and evaluation of potential partners and/or novel technologies aligned with current strategic mandate• Recognized with “Takeda Exceptional Leadership Award” in 2020

Led early Discovery programs on the Attenukine™ platform, an antibody – attenuated interferon alpha fusion protein, in collaboration with TEVA Pharmaceuticals• Discovery lead on clinical team for modakafusp alfa (moda), an anti-CD38 Attenukine™, leading preclinical efforts towards defining key mechanism of action (MOA) and optimal clinical combination strategies for moda, as well as presenting to external stakeholders and KOLs• JSC member on external collaborations with Crescendo Biologics and TEVA Pharmaceuticals

Established strategic priorities and led a non-clinical/translational team in generating data packages to guide clinical development of MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3• Led translational team (6 reports) that robustly characterized the activity and MOA of MM-141 and identified optimal combination agents for clinical testing • Designed and implemented in vivo biomarker and pharmacodynamic strategies to enable MM-141 Phase 1 (multiple indications) and Phase 2 (metastatic pancreatic cancer) studies, and incorporated these contributions into study materials (i.e., clinical protocol, investigator brochure, lab manual) • Lead author on successful FDA application for orphan drug designation for MM-141 in pancreatic cancer in the United States• Advanced clinical opportunities for MM-141 through the formation of external collaborations and research agreements with academic institutions/CROs• Presented pre-clinical research findings/strategy and early clinical data to senior leadership, scientific advisory boards, clinical investigators, and external audiences for business development purposes

Spearheaded multiple pre-clinical research efforts to generate data packages to support the clinical development of MM-121, an anti-ErbB3 antibody, for multiple Phase 2 trials.• Delivered oral presentation at AACR and composed a manuscript (Curley et al. MCT, 2015) characterizing the activity of MM-121 in combination with an aromatase inhibitor in a preclinical model of post-menopausal breast cancer in collaboration with academic investigators

• Optimized patient-derived xenograft mouse model of primary human ovarian tumors, which led to the identification and characterization of CD133 as a marker of ovarian tumor-initiating cells using multi-parameter flow cytometry (Curley et al. Stem Cells, 2009)